An in-depth look to Citius Pharmaceuticals, Inc. operating, investing, and financing activities

CTXR free cash flow for Q3 24 is -8.37 M USD. For 2023, CTXR free cash flow was -29.06 M USD and operating cash flow was -29.06 M USD.